Clovis Oncology Inc. (NASDAQ:CLVS) traded at $2.56 at last check on Monday, January 10, made an upward move of 0.20% on its previous day’s price.
Looking at the stock we see that its previous close was $2.55 and the beta (5Y monthly) reads 1.67 with the day’s price range being $2.55 – $2.82. In terms of its 52-week price range, CLVS has a high of $11.10 and a low of $2.55. The company’s stock has lost about -19.30% over that past 30 days.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Clovis Oncology Inc. has a market cap of $352.21 million and is expected to release its quarterly earnings report on Feb 21, 2022 – Feb 25, 2022. Estimates by analysts give the company expected earnings per share (EPS) of -$0.56, with the EPS growth for the year raised at -$2.32 for 2021 and -$1.4 for next year. These figures represent 47.00% and 39.70% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $40.03 million, with a low of $39 million and a high of $41.5 million. The median projection represents growth adding up to -7.50% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $152.63 million, or -7.20% down from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the CLVS stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Based on estimates by 4 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Clovis Oncology Inc. (CLVS) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 1 of them rated it as underweight, whereas 1 suggest the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is -11.21% off its SMA20 and -23.99% from its 50-day simple moving average. The RSI (14) is pointing at 38.91 while the volatility over the past week is 10.53% and jumps to 9.15% over the past one month. The beta value is 1.58, while the average true range (ATR) is currently pointing at 0.26. The average price target for the stock over the next 12 months is $6.33, with the estimates having a low of $5.00 and a high of $8.00. These price ends are -95.31% and -212.5% off the today’s price level respectively, although investors could be excited at the prospect of a -134.38% if the CLVS share price touches on the median price of $6.00.
Let’s briefly compare Clovis Oncology Inc. (CLVS) stock to its peers. We find that today’s price change of 0.20% and -49.50% over the past 12 months for CLVS competes that of Eli Lilly and Company (LLY), which has seen its stock price fall -1.08% in the latest trading session and is 55.94% over the last one year. Another of its peers AstraZeneca PLC (AZN) has dropped -1.70% today, and was 13.02% up over the past year, while Johnson & Johnson (JNJ) is also down -0.70% yet, while its price remains in the green at 8.69% over the same period. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -2.01% and -1.63%, respectively, in early deals.
Coming back to Clovis Oncology Inc. (NASDAQ:CLVS), we note that the average 3-month trading volume was 3.47 million, while that of the preceding 10-day period stands at 3.95 million. Current shares outstanding are 129.98 million.
The insiders hold 0.40% of the company’s shares while institutions hold 48.60%. The data shows that short shares as of Dec 14, 2021, stood at 26.2 million at a short ratio of 6.1. This represents a 20.16% short interest in shares outstanding on Dec 14, 2021. Shares short fall in December from the previous month at 26.47 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -5.90% down in year-to-date price movement.